JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Fundamental Analysis

NASDAQ:JAZZ • IE00B4Q5ZN47

166.31 USD
+0.02 (+0.01%)
At close: Feb 13, 2026
166.31 USD
0 (0%)
After Hours: 2/13/2026, 8:18:31 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to JAZZ. JAZZ was compared to 191 industry peers in the Pharmaceuticals industry. JAZZ has a medium profitability rating, but doesn't score so well on its financial health evaluation. JAZZ may be a bit undervalued, certainly considering the very reasonable score on growth


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year JAZZ was profitable.
  • In the past year JAZZ had a positive cash flow from operations.
  • In multiple years JAZZ reported negative net income over the last 5 years.
  • JAZZ had a positive operating cash flow in each of the past 5 years.
JAZZ Yearly Net Income VS EBIT VS OCF VS FCFJAZZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

  • JAZZ has a better Return On Assets (-3.24%) than 74.35% of its industry peers.
  • Looking at the Return On Equity, with a value of -9.31%, JAZZ is in the better half of the industry, outperforming 75.39% of the companies in the same industry.
  • JAZZ's Return On Invested Capital of 3.95% is amongst the best of the industry. JAZZ outperforms 82.20% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for JAZZ is significantly below the industry average of 12.64%.
  • The 3 year average ROIC (3.85%) for JAZZ is below the current ROIC(3.95%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -3.24%
ROE -9.31%
ROIC 3.95%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
JAZZ Yearly ROA, ROE, ROICJAZZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 15 20

1.3 Margins

  • JAZZ's Profit Margin has declined in the last couple of years.
  • The Operating Margin of JAZZ (10.92%) is better than 83.25% of its industry peers.
  • In the last couple of years the Operating Margin of JAZZ has declined.
  • JAZZ's Gross Margin of 88.49% is amongst the best of the industry. JAZZ outperforms 90.05% of its industry peers.
  • In the last couple of years the Gross Margin of JAZZ has remained more or less at the same level.
Industry RankSector Rank
OM 10.92%
PM (TTM) N/A
GM 88.49%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
JAZZ Yearly Profit, Operating, Gross MarginsJAZZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), JAZZ is destroying value.
  • The number of shares outstanding for JAZZ has been reduced compared to 1 year ago.
  • Compared to 5 years ago, JAZZ has more shares outstanding
  • The debt/assets ratio for JAZZ is higher compared to a year ago.
JAZZ Yearly Shares OutstandingJAZZ Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
JAZZ Yearly Total Debt VS Total AssetsJAZZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • JAZZ has an Altman-Z score of 1.53. This is a bad value and indicates that JAZZ is not financially healthy and even has some risk of bankruptcy.
  • JAZZ has a Altman-Z score (1.53) which is comparable to the rest of the industry.
  • JAZZ has a debt to FCF ratio of 4.33. This is a neutral value as JAZZ would need 4.33 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 4.33, JAZZ belongs to the best of the industry, outperforming 84.82% of the companies in the same industry.
  • JAZZ has a Debt/Equity ratio of 1.09. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 1.09, JAZZ is doing worse than 73.82% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF 4.33
Altman-Z 1.53
ROIC/WACC0.52
WACC7.65%
JAZZ Yearly LT Debt VS Equity VS FCFJAZZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.3 Liquidity

  • A Current Ratio of 1.65 indicates that JAZZ should not have too much problems paying its short term obligations.
  • JAZZ has a worse Current ratio (1.65) than 68.06% of its industry peers.
  • A Quick Ratio of 1.44 indicates that JAZZ should not have too much problems paying its short term obligations.
  • JAZZ has a worse Quick ratio (1.44) than 63.87% of its industry peers.
Industry RankSector Rank
Current Ratio 1.65
Quick Ratio 1.44
JAZZ Yearly Current Assets VS Current LiabilitesJAZZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • JAZZ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -58.39%.
  • The Earnings Per Share has been growing slightly by 5.47% on average over the past years.
  • JAZZ shows a small growth in Revenue. In the last year, the Revenue has grown by 4.14%.
  • JAZZ shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.48% yearly.
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%

3.2 Future

  • Based on estimates for the next years, JAZZ will show a small growth in Earnings Per Share. The EPS will grow by 7.67% on average per year.
  • Based on estimates for the next years, JAZZ will show a small growth in Revenue. The Revenue will grow by 7.06% on average per year.
EPS Next Y-60.74%
EPS Next 2Y4.5%
EPS Next 3Y6.57%
EPS Next 5Y7.67%
Revenue Next Year4.8%
Revenue Next 2Y5.63%
Revenue Next 3Y6.42%
Revenue Next 5Y7.06%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
JAZZ Yearly Revenue VS EstimatesJAZZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
JAZZ Yearly EPS VS EstimatesJAZZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 20.38, JAZZ is valued on the expensive side.
  • Based on the Price/Earnings ratio, JAZZ is valued cheaply inside the industry as 81.15% of the companies are valued more expensively.
  • JAZZ's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.97.
  • A Price/Forward Earnings ratio of 7.19 indicates a rather cheap valuation of JAZZ.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 93.19% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.96, JAZZ is valued rather cheaply.
Industry RankSector Rank
PE 20.38
Fwd PE 7.19
JAZZ Price Earnings VS Forward Price EarningsJAZZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, JAZZ is valued cheaper than 87.96% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, JAZZ is valued cheaply inside the industry as 93.72% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 8.16
EV/EBITDA 11.15
JAZZ Per share dataJAZZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 -40 60

4.3 Compensation for Growth

  • The decent profitability rating of JAZZ may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.73
EPS Next 2Y4.5%
EPS Next 3Y6.57%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • JAZZ does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

JAZZ PHARMACEUTICALS PLC

NASDAQ:JAZZ (2/13/2026, 8:18:31 PM)

After market: 166.31 0 (0%)

166.31

+0.02 (+0.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05
Earnings (Next)03-03
Inst Owners104.02%
Inst Owner Change-2.3%
Ins Owners2.48%
Ins Owner Change-0.21%
Market Cap10.11B
Revenue(TTM)4.16B
Net Income(TTM)-368.48M
Analysts85.22
Price Target221.83 (33.38%)
Short Float %9.08%
Short Ratio4.9
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.15%
Min EPS beat(2)-6.35%
Max EPS beat(2)34.65%
EPS beat(4)2
Avg EPS beat(4)-6.25%
Min EPS beat(4)-64.64%
Max EPS beat(4)34.65%
EPS beat(8)4
Avg EPS beat(8)-5.06%
EPS beat(12)4
Avg EPS beat(12)-14.55%
EPS beat(16)7
Avg EPS beat(16)-9.8%
Revenue beat(2)0
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)-0.43%
Revenue beat(4)1
Avg Revenue beat(4)-3.13%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.27%
Revenue beat(16)3
Avg Revenue beat(16)-2.04%
PT rev (1m)1.93%
PT rev (3m)14.73%
EPS NQ rev (1m)1.33%
EPS NQ rev (3m)11.94%
EPS NY rev (1m)1.1%
EPS NY rev (3m)53.36%
Revenue NQ rev (1m)0.85%
Revenue NQ rev (3m)-0.34%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)0.42%
Valuation
Industry RankSector Rank
PE 20.38
Fwd PE 7.19
P/S 2.43
P/FCF 8.16
P/OCF 7.26
P/B 2.55
P/tB N/A
EV/EBITDA 11.15
EPS(TTM)8.16
EY4.91%
EPS(NY)23.14
Fwd EY13.91%
FCF(TTM)20.39
FCFY12.26%
OCF(TTM)22.9
OCFY13.77%
SpS68.42
BVpS65.15
TBVpS-40.06
PEG (NY)N/A
PEG (5Y)3.73
Graham Number109.37
Profitability
Industry RankSector Rank
ROA -3.24%
ROE -9.31%
ROCE 5%
ROIC 3.95%
ROICexc 5.1%
ROICexgc 55.75%
OM 10.92%
PM (TTM) N/A
GM 88.49%
FCFM 29.8%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexgc growth 3Y32.25%
ROICexgc growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF 4.33
Debt/EBITDA 3.8
Cap/Depr 22.29%
Cap/Sales 3.68%
Interest Coverage 250
Cash Conversion 122.16%
Profit Quality N/A
Current Ratio 1.65
Quick Ratio 1.44
Altman-Z 1.53
F-Score5
WACC7.65%
ROIC/WACC0.52
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
EPS Next Y-60.74%
EPS Next 2Y4.5%
EPS Next 3Y6.57%
EPS Next 5Y7.67%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
Revenue Next Year4.8%
Revenue Next 2Y5.63%
Revenue Next 3Y6.42%
Revenue Next 5Y7.06%
EBIT growth 1Y-35.5%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-57.7%
EBIT Next 3Y5.83%
EBIT Next 5Y7.65%
FCF growth 1Y42.84%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y9.88%
OCF growth 3Y21.49%
OCF growth 5Y12.45%

JAZZ PHARMACEUTICALS PLC / JAZZ FAQ

Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?

ChartMill assigns a fundamental rating of 4 / 10 to JAZZ.


Can you provide the valuation status for JAZZ PHARMACEUTICALS PLC?

ChartMill assigns a valuation rating of 7 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Undervalued.


Can you provide the profitability details for JAZZ PHARMACEUTICALS PLC?

JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 6 / 10.


Can you provide the financial health for JAZZ stock?

The financial health rating of JAZZ PHARMACEUTICALS PLC (JAZZ) is 3 / 10.


What is the expected EPS growth for JAZZ PHARMACEUTICALS PLC (JAZZ) stock?

The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to decline by -60.74% in the next year.